James Rolke
Chief Executive Officer at REVELATION BIOSCIENCES, INC.
Net worth: 1 451 $ as of 29/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
George Tidmarsh | M | 64 |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | 12 years |
Chester Zygmont | M | 44 |
Revelation Therapeutics LLC
Revelation Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Revelation Therapeutics LLC provides biotechnology services. The company is headquartered in Menlo Park, CA. | 9 years |
Jennifer Carver | F | 70 |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | 10 years |
Sandra Vedrick | F | - | 7 years | |
Curt LaBelle | M | 53 |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | 3 years |
Jess Roper | M | 59 |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | 4 years |
Lakhmir Chawla | M | 53 | 7 years | |
Luke Seikkula | M | 60 | 5 years | |
Paula Rusu | F | - | 4 years | |
Robin Marsden | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Nicholas Bacopoulos | M | 75 | - | |
Dennis Mulroy | M | 69 | 5 years | |
Saiid Zarrabian | M | 71 | - | |
Deirdre Y. Gillespie | M | 67 | 6 years | |
Robert A. Fildes | M | 85 | 21 years | |
Gail A. Sloan | F | 61 | 16 years | |
Daniel Gold | M | 70 |
Prospect Therapeutics, Inc.
Prospect Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Prospect Therapeutics, Inc. develops biopharmaceuticals to treat variety of cancers. The firm's products include GCS-100, for the treatment of leukemia, multiple myeloma and lymphoma, GCS-100, a proprietary polysaccharide, targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis. The company was founded by Joseph Grimm, George Tidmarsh, and Kevin Tang in July 2006 and is headquartered in Woburn, MA. | 1 years |
Jeffrey Jensen | M | - | - | |
Robert H. Rosen | M | 68 | 8 years | |
Craig Johnson | M | 62 | 9 years | |
Laura Douglass | F | 59 | 9 years | |
David Ramsay | M | 59 | 3 years | |
Inge Bear | F | - | - | |
Carol Odle | F | - | 2 years | |
Christopher Galloway | M | 53 | 2 years | |
Darryl Wellinghoff | M | 55 | 1 years | |
Joseph Ninosky | M | - | 1 years | |
Clara Ezed | F | 52 | 3 years | |
Wayne Coll | M | 60 |
Pluromed, Inc.
Pluromed, Inc. Medical SpecialtiesHealth Technology Pluromed, Inc. manufactures and markets disposable medical devices that are used to control bleeding during surgery. The company's trademark products include LeGoo Internal Vessel Occluder and BackStop. It was founded in 2003 and is located in Woburn, MA. | 2 years |
Thomas J. Ouellette | M | - | 1 years | |
Stewart M. Kroll | M | 65 | 5 years | |
Bertrand C. Liang | M | 61 | 2 years | |
Guy M. Gammon | M | - |
Prospect Therapeutics, Inc.
Prospect Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Prospect Therapeutics, Inc. develops biopharmaceuticals to treat variety of cancers. The firm's products include GCS-100, for the treatment of leukemia, multiple myeloma and lymphoma, GCS-100, a proprietary polysaccharide, targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis. The company was founded by Joseph Grimm, George Tidmarsh, and Kevin Tang in July 2006 and is headquartered in Woburn, MA. | - |
Kevin Tang | M | 57 | 8 years | |
Michael E. Hanson | M | 74 |
Glycogenesys, Inc.
Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | 4 years |
Brent Rutland | M | - | 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 36 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James Rolke
- Personal Network